Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A

Vikas, P., Korde, L. A., Somerfield, M. R., & Hershman, D. L. (2022). Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncology Practice, 18(9), 649–651. https://doi.org/10.1200/op.22.00284